Opinion|Videos|January 6, 2026
Current Expectations With Commercial Manufacturing of CAR T-Cell Therapy
Maximilian Merz, MD, and Carrie Bellerive, BS, RN, BMTCN, detail current expectations with manufacturing processes for CAR T-cell therapy.
Advertisement
Episodes in this series
Maximilian Merz, MD, and Carrie Bellerive, BS, RN, BMTCN, detail current expectations and realities surrounding commercial manufacturing of CAR T-cell therapies. They discuss timelines, quality control considerations, and logistical challenges that can affect treatment planning. Merz and Bellerive also address how evolving manufacturing processes may improve access and reliability over time.
Advertisement
Related to this article
Data from EXCALIBER-RRMM supported FDA accelerated approval of iberdomide plus daratumumab/dexamethasone in R/R multiple myeloma.
The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.
Pankit Vachhani, MD, discusses the importance of hematocrit control in the management of polycythemia vera.
Pembrolizumab plus denosumab produced a 31% ORR and 53% 6-month PFS rate in VEGFR-TKI-pretreated advanced clear cell renal cell carcinoma.
A new study suggests genomic newborn screening could identify children at risk for early cancers and enable earlier diagnosis and less toxic treatment.
The CLDN18.2/CD47 bispecific antibody spevatamig has received FDA fast track designation for advanced and metastatic biliary tract carcinoma.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Hamza Hashmi, MD, discusses the evolving role and implementation of CAR T-cell therapy in early relapsed/refractory multiple myeloma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
2
The OncFive: Top Oncology Articles for the Week of 8/9
3
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
4
Novel Approaches for Hematocrit Control Are Driving Research in Polycythemia Vera
5